Ligand to Acquire Ab Initio Biotherapeutics for its Antigen Technology
Shots:
- Ligand will acquire Ab Initio for $12M in cash as Ab Initio’s antigen technology is complimenting Ligand’s OmniAb therapeutic antibody discovery platform which will further strengthen and expand ligand’s OmniAb offerings
- In 2016- Ab Initio and Pfizer collaborated to develop AB against GPCR- post-acquisition Ligand will receive milestones and royalties on sales of targeted Abs
- Ligand's OmniAb antibody platform produces naturally optimized human antibodies while Ab Initio’s antigen discovery platform targets multi-transmembrane proteins like GPCRs and advance Ab for multiple therapeutic indications including neurological- cardiovascular- endocrine and gastrointestinal disorders
Click here to read full press release/ article | Ref: Ligand | Image: JLabs
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com